Thomas Mundorf, MD
Ophthalmology · Charlotte, NCNPI 1821026980
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $167,019 of the $220,296 with a category attached, or 75.8%. 15 manufacturers reported payments, led by AbbVie at 50.0% of the total. Reporting peaked in 2019 at $81,434 and has fallen 99.8% since, to $125 in 2025. Among ophthalmology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 499 payments — averaging $441.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$110K
- Aerie Pharmaceuticals, Inc.$85K
- Iridex Corporation$16K
- Alcon$6K
- Perrigo Company PLC$1K
- Amgen$398
- plus $1K from 9 others
Across 17 payments — averaging $5682.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Padagis US LLC$64K
- AbbVie$30K
- Perrigo Company PLC$3K
What the payments were for
- Consulting fees$7,1883%
- Speaking & faculty fees$167,01976%
- Travel & lodging$36,34516%
- Food & beverage$9,5274%
- Education$2180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 338 | $110,178 |
| Aerie Pharmaceuticals, Inc. | 96 | $84,598 |
| Iridex Corporation | 5 | $16,022 |
| Alcon | 16 | $6,355 |
| Perrigo Company PLC | 2 | $1,383 |
| Amgen(2 entities) | 8 | $398 |
| Bausch & Lomb Americas Inc. | 15 | $312 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $289 |
| Tarsus Pharmaceuticals, Inc. | 3 | $286 |
| Astellas Pharma US Inc | 1 | $129 |
| Dompe US, Inc. | 1 | $101 |
| Biotissue Holdings Inc. | 1 | $99 |
| Novartis | 2 | $60 |
| Sun Pharmaceutical Industries Inc. | 2 | $45 |
| Carl Zeiss Meditec USA, Inc. | 2 | $42 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$220,296 in reported general payments places this provider in the 95th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 203 | $114,763 |
| RestasisCyclosporine | 58 | $71,842 |
| RhopressaNetarsudil Mesylate | 88 | $67,482 |
| CombiganBrimonidine Tartrate/Timolol | 145 | $65,376 |
| RocklatanNetarsudil Mesylat/Latanoprost | 40 | $33,299 |
| XdemvyLotilaner | 13 | $25,195 |
| XiidraLifitegrast | 12 | $17,775 |
| Alphagan PBrimonidine Tartrate | 36 | $15,659 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 72 | $13,919 |
| VyzultaLatanoprostene Bunod | 23 | $11,566 |
| Latanoprost | 366 | $4,715 |
| Travoprost | 22 | $4,234 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 192 | $3,483 |
| Dorzolamide Hcl | 148 | $3,064 |
| Brimonidine Tartrate | 161 | $1,859 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $110,178 | $267,640442 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $84,598 | $100,781128 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $312 | $29,34135 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $286 | $25,19513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 588 ophthalmology providers in North Carolina.
Other ophthalmology in Charlotte
- Charles BlotnickCharlotte$18K
- Adrian ElfersyCharlotte$13K
- Joseph KrugCharlotte$10K
- Royce SyracuseCharlotte$10K
- William HammondsCharlotte$9K
- Preeya GuptaRaleigh$1.8M
- Julie WoodwardDurham$1M
- Rajiv ShahWinston Salem$909K
- Lejla VajzovicDurham$681K
- Karl StonecipherGreensboro$653K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.